Re-implantation after insufficient primary 125-i permanent prostate brachytherapy by Paul Putora et al.
Putora et al. Radiation Oncology 2013, 8:194
http://www.ro-journal.com/content/8/1/194RESEARCH Open AccessRe-implantation after insufficient primary 125-i
permanent prostate brachytherapy
Paul Martin Putora1*, Ludwig Plasswilm1, Wolf Seelentag1, Johann Schiefer1, Patrick Markart2,
Hans-Peter Schmid2 and Daniel Engeler2Abstract
Introduction: We describe five patients receiving a re-implantation (RI) after post-operative dosimetry of the
primary 125-I permanent prostate brachytherapy (BT) for prostate cancer revealed an insufficient dose coverage.
Materials and methods: Five out of 222 consecutive patients treated (from March, 2001 to August, 2012) with
125-I BT, received a RI after dosimetric verification by CT and MRI fusion four to eight weeks after implantation
displayed an insufficient dose coverage. RIs were performed with 10 to 19 seeds, three to four months after primary
intervention. Dosimetry after RI showed an improved and sufficient total dose coverage in all patients.
Results: At last follow-up (18 to 99 months, median 57 months), none of the patients had relevant implant
associated side-effects. Functional outcome was comparable to patients after one-time implantation. PSA levels
post intervention showed a decreasing tendency in 4 patients. One patient had a local recurrence after 12 months.
Conclusion: In our series, approximately 2% of the patients treated with permanent prostate BT required a RI due
to insufficient dose coverage. None of the patients who underwent RI experienced complications. Our series,
although only with 5 cases and limited follow-up, along with other published reports, demonstrates good tolerability.
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Prostate cancer (PC) is the most common solid neoplasm
and the second most common cause of cancer death in
men. Due to the increasing use of prostate-specific anti-
gen (PSA) testing, the diagnosis of PC is rising world-
wide. Most the new cases are diagnosed early with low
PSA and Gleason scores. For these patients, permanent
seed prostate brachytherapy (BT) is a treatment option
associated with low morbidity and similar oncological
outcome as with radical prostatectomy or external beam
radiation therapy [1-3]. For the oncological long-term
success of BT, it is important to ensure the prostate is
covered with sufficient dose. Prostate cancer foci occur-
ring in areas with insufficient dose may lead to recurrence.
The most frequently used parameters to assess quality of
implantation in BT are the volume of the prostate covered
by 100% of the prescribed dose (V100) and the dose* Correspondence: paul.putora@kssg.ch
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reproduction in any medium, provided the orcovering 90% of the prostate volume (D90) [4]. The decline
of dose coverage between intraoperative planning and post
implant dosimetry is a known phenomenon. For per-
manent 125-I seed implantation, loose or stranded seed
methods can be used. As published by a Dutch group,
the stranded seed method seems to have a higher rate
of dose decline. The compared methods were RAPID
strand, Intersource strand and loose selectSeeds, the de-
cline of D90 was 40 Gy, 25 Gy and 15 Gy on average [5].
There are several reports linking postimplant dosimetry
to biochemical outcome. The first report showing higher
biochemical relapse rates for patients with D90 of <140 Gy
was by Stock & Stone [6]. The American Brachyther-
apy Society suggested that implants should meet the
D90 >130 Gy dosimetric criterium [7] because lower doses
are associated with an increased risk of oncological failure
[8]. Whereas the criteria for excellent postimplant dos-
imetry are well accepted, the dose limits that should
prompt salvage treatment by external beam radiotherapy or
reimplantation (RI) are not clear. In general, permanent
prostate seed BT is a well tolerated treatment, but evaluationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sults is mandatory. If a RI is planned, toxicity caused by
the second intervention may be an issue and must be con-
sidered. Because of sparsity of reports on RI, we herein de-
scribe our experience with five patients receiving a RI
after dosimetry of the primary 125-I permanent prostate
BT revealed insufficient dose coverage.
Material and methods
Patient selection for permanent seed prostate
brachytherapy
At our institution, patients are eligible for permanent
seed 125-I prostate BT as a monotherapy if they are di-
agnosed with localized low-risk prostate cancer (PSA < =
10 ng/dl, Gleason score < =6, clinical stage T1 to T2a),
or occasionally with intermediate prostate cancer (either
PSA 10-20 ng/dl, Gleason score 7, or clinical stage T2b).
For the application several seed types were used:
Rapidstrand (first patient described here), IsoCord S06
(second patient) and IsoCord S17 (last three patients),
respectively. Seed activity used is typically in the range
0.70 to 0.78 mCi/Seed, depending on the size of the
prostate. The activity is chosen to result in approxi-
mately 40-60 seeds for the implantation.
Patients up to 75 years of age are treated depending
on their individual life expectancy. Patients with prostate
volumes >60 ml undergo preoperative downsizing with
3 months of hormonal therapy using Luteinizing-hormone-
releasing hormone agonists.
Patient evaluation and follow-up
Besides oncological parameters including digital rectal
examination, PSA, transrectal ultrasound, biopsy Gleason
grade, staging examinations (computed tomography of
the pelvis and bone scan) clinical functional data were
recorded routinely. They included residual urine volume,
maximum urine flow rate (Q-max), international prostate
symptom score (IPSS), and IPSS-quality of life (IPSS-
QoL) [9]. Genitourinary, gastrointestinal and musculo-
skeletal adverse events were recorded according to the
National Cancer Institute common toxicity criteria (CTCAETable 1 Micturition parameters baseline and after treatment

























As control, mean values of 144 consecutive patients treated without re-implantation
second the control group consisting of patients not receiving a re-implantation. (IPSv3.0) [10]. Follow-up examinations were scheduled at six
weeks, six months, one year, and yearly thereafter. The
median follow-up was 57 months (ranging from 18-99
months). For comparison of micturition and quality of
life data from patients treated at our institution with
primary implantation only were compiled (see Table 1).
Implant planning and procedure
The method implemented was an intraoperatively planned
template-guided transrectal ultrasound-guided permanent
125-I BT. This method is established and has demon-
strated excellent prostate dosimetry results and rectal
sparing [11].
Implantation procedure
The prostate structure was defined in ultrasound images
by the urologist. The planning procedure is then a multi-
disciplinary process involving the urologist, radiation-
oncologist and medical physicist. The preplan is used
only to determine the approximate number of seeds re-
quired. At the day of the implantation the ultrasound
probe and template are fixed and ultrasound images are
aquired. Based on these the prostate is contoured and a
plan calculated. The prescribed dose is 145 Gy to the pros-
tate. The dosimetric criteria were V100%prostate ≥ 95% of
the prostate structure volume. The maximal urethral dose
was aimed to be kept less than 150% of the prescribed
dose. The volume of the rectum receiving 100% of the
prescribed dose was aimed to be kept under 0.3 cm3. The
seeds were implanted through the template under biplanar
ultrasound guidance, additionally longitudinal placement
is verified by X-ray; only in rare cases of deviations during
implantation the plan needs to be adapted in real-time.
On the same or next day of implantation a conven-
tional x-ray anterio-posterior is performed for immedi-
ate documentation.
Postimplantation dosimetry
Six weeks (on average) post implant MRI and CT scans
of the pelvis were acquired. The dose distribution is calcu-
lated on MR-CT fusion images to determine whether the(mean values and range)

































are shown. The first line shows the values for the re-implanted patients, the
S data was available for 3,3,4,3,2,2 patients respectively).
Table 2 Basic oncological parameters of patients undergoing reimplantation
Pt. No. Age (years) T stage Gleason score Init. PSA (ng/ml) Nadir PSA (ng/ml) F/U (months) Last PSA (ng/ml)
1 45 T2a 4(2 + 2) 6.5 0.18 99 0.18
2 54 T1c 6(3 + 3) 6.7 0.03 80 0.03
3 53 T1c 6(3 + 3) 3.68 0.02 57 0.02
4 67 T1c 6(3 + 3) 12.8 2.07 43 10.1
5 60 T1c 6(3 + 3) 5.09 1.33 18 1.33
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by the American Brachytherapy Society [7].Decision criteria for reimplantation
Decision criteria were based on a case-to-case basis de-
termined by insufficient dose coverage (D80 below 100%
or V100 below 80%) and patient preference. As the
reimplantation is not considered a standard procedure,
only larger deviations from the expected dose coverage
would warrant a reimplantation, this is why the D80 was
used as parameter instead of D90.Salvage procedure
The salvage re-implantation procedure is prepared based
on the postimplant MR and CT scans. The distribution
of the additionally needed seeds (same activity as in the
primary seed application) is then transferred to the tem-
plate positions intraoperatively to cover the cold spots.
Six weeks after re-implantation CT and MRI scans are
performed again for dose calculations. The time gap is
not incorporated in dose calculations. The dose coverage
goals and consideration of the organs-at-risk were basic-
ally the same as in the primary implantation.Results
Out of 222 consecutive patients treated (from 2001 to
August 2012) with 125-I permanent prostate BT in five
patients (2.3%) RI was performed. In all five patients the
RI was performed three to four months after the primary
intervention. We performed a detailed review of all five
cases including their dosimetric parameters, oncological
and functional follow-up.Table 3 Maximal urinary and rectal toxicities as well as corres
D5u (%) Maximal urinary toxicity Time
Patient 1 150.0 0
Patient 2 161.4 frequency, grade 1
Patient 3 131.1 pain, grade 1
Patient 4 129.9 0
Patient 5 153.7 retention, grade 1
V100r – the rectal volume receiving at least 100% of the prescribed dose. D5u – theSummary of all reimplanted patients
All patients undergoing salvage RI had localized low-risk
prostate cancer at diagnosis (Table 2). No relevant differ-
ences in terms of residual urine, Qmax or IPSS and
IPSS-QoL could be observed in the RI group when com-
pared to the control group (217 patients without RI)
(Table 1).
The minimal dose to 5% of the urethra volume (D5u),
representing the maximum dose to urethra, was similar
to patients without a re-implantation. To put this into
perspective, intra-operative dosimetric data of the last
166 patients were retrieved from our database. The aver-
age D5u of patients receiving a brachytherapy for pros-
tate cancer was 143% (ranging from 126% to 177%), the
median being 137%.
The rectal volume receiving at least 100% of the prescribed
dose for patients undergoing a re-implantation is also de-
scribed in Table 3. The same 166 patients were evaluated.
The average for patients not undergoing a re-implantation
was 0.22 (range from 0 to 2.7), median 0.26 cm3.
The objective parameters and IPSS quality of life scores
showed a temporary worsening and a trend towards
normalization after approximately one to two years. This
is a typical observation in brachytherapy for prostate can-
cer and not specific for RIs.
At 6 weeks after reimplantation none of the patients
experienced any toxicity. At 6 months patient 3 experi-
enced genitourinary pain grade 1 and patient 5 urinary re-
tention grade 1. At one year both normalised (grade 0).
Patient 2 experienced urinary frequency/urgency grade 1,
which also normalised by the 2 year follow-up. Other tox-
icity was not observed.
The number of seeds used for primary as well as
secondary implantation together with the dosimetricponding dosimetric parameters
point of toxicity V100r (cm3) Maximal rectal toxicity
- 0.1 0
2 years 0.3 0
6 months 0.3 0
- 0.3 0
6 months 0.9 0
minimum dose to 5% of the urethra volume.




Seeds used at implantation,
in brackets the seeds






1 50 12 34.9 37.2
2 56 16 31.5 30.8
3 51 (48) 19 (17) 40.3 40.8
4 42 12 43.8 31.7
5 49 10 40.0 42.5
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RI are described in Tables 4 and 5. Single seed migration
is not enough to cause a significant underdosage requiring
a RI procedure. In all 5 cases where a RI was conducted
the underdosage was caused by multiple seeds. Of the last
166 patients consecutively treated and digitally docu-
mented a total of 6 patients had a primary implantation
that would qualify for a re-implantation. Of these in two
cases a re-implantation was not considered appropriate,
the other four received a re-implantation. Based on this
we would estimate the rate of ‘unacceptable’ implanta-
tions to be about 1 in 25.
The PSA values of the patients are shown in Figure 1.
Two patients experienced a bounce phenomenon, a tran-
sient increase in PSA value after brachytherapy. Patient
number 4 experienced a biochemical failure.
A sample case
To demonstrate the problem a sample case is described
here (patient No. 3 in tables). The underdosed prostate
values were caused by a shift of the implanted 48 seeds
caudally from the planned position, additionally 3 seeds
were lost (Figure 1). The re-implantation was performed
with 19 seeds, however two were lost here as well resulting
in 17 re-implantation seeds. The dose coverage in theTable 5 Dosimetric parameters after primary (p) and seconda
Patient number D90p [%] V50 [cm3] V100 [cm3
p s p s p s
1 62.8 104.4 106.5 126.4 52.6 6
2 67.6 140.2 160.9 215.6 76.7 1
3 57.2 123.5 112.7 161.2 55.4 8
4 77.0 107.9 110.5 132.5 47.7 6
5 61.7 95.9 130.1 162.5 59.8 8
Median control 105.4 142.7 70.5
(D90p – the percentage of the prescribed dose covering 90% of the prostate volum
prescribed dose respectively, V100p, V150 – the volume of the prostate in cm3 rece
The median values of a control group of 165 consecutive patients was added as copostoperative CT/MRI fusion images of the primary im-
plantation was clearly insufficient in this situation (D90
57.2%, D80 75.98%), thus the decision for RI was taken.
The resulting dose distribution was significantly better
after RI (D90 123.5%). The reason for the massive shift
remains unclear as the ultrasound and guided place-
ment was as inconspicuous. To put this into perspec-
tive, of the last 161 consecutive patients (including the
last three re-implantations) seed loss was detected in
34% of patients. Of these 13% had single seed loss, 19%
had 2-4 seeds lost and in three cases 5, 9 and 10 seeds
were lost respectively.Recurrence
In one out of the five patients (Patient number 4), after
reaching a nadir of 0.5, a recurrence was detected
22 months after salvage RI. The recurrence was detected
by a PSA rise (up to 18.9 ng/ml). The recurrence rate at
our institution for patients treated with primary iodine
seed brachytherapy was 6.8% at 5 years based on patient
data with at least 2 years of follow up (195 evaluable
patients). A 18 F-choline PET/CT was performed, where
a solitary choline uptake could be identified amidst
artifacts from brachytherapy seeds. The dosimetric pa-
rameters of the patient were satisfactory after RI. The
specific location of recurrence could not be identified
as underdosed on retrospective review. Based on patient
preference and pre-irradiation further surgery or radiother-
apy was refrained from. After intersdisciplinary discussion
the decision was taken to perform a High Intensity Focal
Ultrasound (HIFU) ablation of the prostate, additionally
to this an androgen deprivation therapy was performed
with an LHRH agonist for 6 months. As a result of this
the PSA decreased to 0.3 ng/ml but has gradually been
rising again to over 10 ng/ml after stopping hormonal
therapy. A bladder neck resection was performed and a
transurethral resection of the prostate including bladder
stone lithotripsy. The resulting histology of the prostatery (s) implantation
] V150 [cm3] V100p [cm3] V150p [cm3]
p s p s p s
2.7 32.6 37.6 25.5 34.1 19.5 25.5
06.9 45.8 66.4 23.4 30.7 16.1 26.3
2.4 32.9 51.0 27.5 39.4 19.0 32.2
5.0 20.1 40.1 32.4 29.3 14.6 22.9
1.7 31.7 42.7 26.4 37.4 13.3 19.5
41.7 36.9 27.3
e, V50, V100, V150 – the volume receiving 50%, 100% and 150% of the
iving 100% and 150% of the prescribed dose respectively).
ntrol.
Figure 1 PSA history of 5 patients undergoing prostate seed re-implantation (RI). Patient number 4 had a recurrence at 22 months,
whereas all other patients had no biochemical relapse.
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after re-implantation) the patient is asymptomatic and
being observed without further therapy (See Patient
No. 4, Figure 2).
Discussion
Post-implant dosimetry is essential to determine the
outcome of prostate seed brachytherapy [6]. Urethral
toxicities are feared with doses exceeding 300 Gy. The
concern of toxicity hinders many in deciding to perform
an immediate salvage therapy. In our series of 222 pa-
tients we performed a RI in 5 patients where the dose
coverage was considered unacceptable and a RI clinic-
ally feasible. Many brachytherapy series do not report
grave underdosing; therefore it is difficult to establish
how often this phenomenon occurs in practice.Figure 2 The surface dose to the prostate (color wash)
shows the areas of doses under 145 Gy with non-white
colors. The surface doses of insufficient primary (48 seeds after loss),
and isolated secondary seed placement (17 after loss) are shown in
panels (a) and (b), respectively. The resulting total dose indicates a
good dose coverage of at least 145 Gy (white) throughout the
prostate surface (c).Algorithms to plan RI have been designed and tested
in phantoms, their routine use in practice is not yet
implemented widely to our knowledge [12]. A single case
demonstrating the feasibility was published in 2005 [13].
The cause was a systematic source placement error that
left the base of the prostate significantly underdosed. In
this report a RI increased the percentage of volume receiv-
ing 100% of the prescribed dose (V100) from 46% to 98%
and the dose to 90% of the Volume (D90) from 49 to
201 Gy. In the described report, the urinary morbidity was
increased and was relieved by medication. Alternative
methods involving robotic seed placement have also been
described (in primary implantation) [14].
Another report of seven cases of RI with 125-I pros-
tate brachytherapy after insufficient initial postimplant
dosimetry reported an optimal dosimetric outcome. The
short-term PSA follow-up was favorable. The authors
conclude however that the ultimate benefits and long-
term toxicity remain unknown [15].
Due to a lack of know-how and published evidence a
decision is often not easy to take. In the 5 cases at our
institution, based on the post-implant dosimetry, we
decided to perform a salvage RI. The procedures were
not associated with any relevant side-effects. This of
course needs to be interpreted with caution. The ther-
apy was tolerated well. Patients did not experience
higher urinary toxicity than expected after a regular im-
plant (Table 3). Alltogether, the re-implantations were
well-tolerated.
In our series rectal toxicity was not observed (CTCAE
Score 0); interestingly in the series reported by Keyes et al.
the median VR100 and VR50 (representing the rectal
volume receiving 50% or 100% of the prescribed dose
respectively for the re-implant patients was lower
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at their institution [15].
As insufficient dose coverage is a rather rare event and
not all of these will undergo RI, the resulting absolute
numbers are low. Linked with the rare occurrence, there
is sparse literature on the subject. Based on this fact it is
currently impossible to establish evidence based recom-
mendations for RI after insufficient primary 125-I pros-
tate brachytherapy.
Conclusion
In our patient collective 2,3% (5 of 222) of patients
treated with permanent prostate BT required a RI due to
insufficient dose coverage. Patients undergoing RI after
125-I seed BT did not experience relevant treatment
associated side effects up to this day. There are only
few published reports on RI and longterm data are still
missing. Conclusions on local control are not statisti-
cally significant, due to the low number of 5 patients,
including one local failure. Our series, along with other
published reports, however, demonstrated good toler-
ability. For individual patients a RI should be discussed
after insufficient primary 125-I seed brachytherapy for
low-risk prostate cancer.
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